Quantum-Si Incorporated (QSI) is an Industrial Machinery/Components company listed on NASDAQ. In the last 30 days Quantisnow tracked 7 wire items for QSI, including 3 SEC filings, 2 press releases and news items and 2 earnings updates. The most recent was published Nov 14, 2026.
QSI rankings
Price$1.14-0.05 (-4.20%)
02:30 PM08:45 PM
Financial highlights
Full financials- Revenue, TTM
- $1.26M
- Revenue growth
- -60.2%
- Net income, TTM
- -$85.13M
- Net margin
- -6729.8%
- Free cash flow, TTM
- -$81.38M
- Cash
- $25.58M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks46-67%
2026-05-172026-11-08
Mix2090d
- Other8(40%)
- SEC Filings7(35%)
- Insider3(15%)
- Earnings2(10%)
Activity · 52 weeks9749 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PRQuantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRANFORD, Conn., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that the Compensation Committee of Quantum-Si’s Board of Directors has granted 495,335 restricted stock units ("RSUs") to new employees under the Company’s previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended (the "2023 Inducement Plan"). The RSUs were granted as an inducement material to the new employees becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4). The 2023 Inducement Plan i
- SECSEC Form 10-Q filed by Quantum-Si Incorporated10-Q - Quantum-Si Inc (0001816431) (Filer)
- SECQuantum-Si Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Quantum-Si Inc (0001816431) (Filer)
- PRQuantum-Si Reports Third Quarter 2026 Financial Results and Provides Business UpdateBRANFORD, Conn., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule protein sequencing, today announced financial results for the third quarter ended September 30, 2026. Press Release Highlights Reported third quarter 2026 revenue of $212,000 during the transition period from Platinum® to Proteus, which is expected to continue through the first half of 2027Highlighted interim Proteus performance data presented at World HUPO including approximately 30 times more sequencing output per chamber in a controlled peptide studyHighlighted detection of 19
- PRQuantum-Si to Provide a Business Update and Report Third Quarter 2026 Financial Results on November 5, 2026BRANFORD, Conn., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will provide a business update and report financial results for the third quarter 2026 on Thursday, November 5, 2026. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations.
- SECSEC Form 8-K filed by Quantum-Si Incorporated8-K - Quantum-Si Inc (0001816431) (Filer)
- PRQuantum-Si Regains Compliance with Nasdaq Minimum Bid Price RequirementBRANFORD, Conn., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI," or the "Company"), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that it has received written notice from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market under Listing Rule 5450(a)(1). Nasdaq determined that the closing bid price of the Company’s common stock had been at or above $1.00 per share for at least 10 consecutive business days. A
- SECSEC Form 8-K filed by Quantum-Si Incorporated8-K - Quantum-Si Inc (0001816431) (Filer)
- PRQuantum-Si Demonstrates Detection of 19 Amino Acids in Proteus™ Development ProgramBRANFORD, Conn., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that it has demonstrated detection of 19 amino acids in its Proteus™ development program and is now working to deploy that capability into a developmental sequencing kit for routine use on integrated Proteus instruments. Building on the interim Proteus results presented at the 2026 World HUPO Congress, this latest milestone reflects continued progress in the Company’s amino acid recognizer program and reinforces its confidence that detection of all 20 amino
- SECQuantum-Si Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Quantum-Si Inc (0001816431) (Filer)
- PRQuantum-Si Presents Interim Proteus™ Data at World HUPO 2026 Demonstrating a Significant Step Change in Performance Compared to Platinum® ProBRANFORD, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced interim development results comparing its next-generation Proteus™ platform with its commercially available Platinum® Pro instrument. Using a developmental sequencing kit that detects 18 amino acids, Proteus significantly outperformed Platinum Pro across every key measure, from sequencing scale and accuracy to peptide identification and protein sequence coverage, even though the Proteus instrument, consumable, loading protocol and analysis software are sti
- INSIDERPresident & CEO Hawkins Jeffrey Alan sold $22,611 worth of shares (29,852 units at $0.76), decreasing direct ownership by 0.81% to 3,639,950 units (SEC Form 4) to satisfy withholding tax4 - Quantum-Si Inc (0001816431) (Issuer)
- INSIDERChief Financial Officer Keyes Jeffry R. sold $5,806 worth of shares (7,665 units at $0.76), decreasing direct ownership by 0.44% to 1,716,684 units (SEC Form 4) (for tax liability)4 - Quantum-Si Inc (0001816431) (Issuer)
- INSIDERGC & Corp. Secretary Lapointe Christian sold $10,995 worth of shares (14,516 units at $0.76), decreasing direct ownership by 1% to 1,167,913 units (SEC Form 4) to satisfy tax liability4 - Quantum-Si Inc (0001816431) (Issuer)
- SECSEC Form 144 filed by Quantum-Si Incorporated144 - Quantum-Si Inc (0001816431) (Subject)
- SECSEC Form 144 filed by Quantum-Si Incorporated144 - Quantum-Si Inc (0001816431) (Subject)
- PRQuantum-Si Announces Detection of 18 Amino Acids Using a Developmental Sequencing Kit on Proteus™BRANFORD, Conn., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that it has demonstrated sequencing with detection of 18 amino acids using a developmental kit run on integrated Proteus™ instruments. The Company continues to expect to demonstrate detection of all 20 amino acids in 2026. "Demonstrating detection of 18 amino acids and incorporating that capability into a developmental sequencing kit that has been successfully run on integrated Proteus instruments is a significant milestone for our company," said Jeff Haw
- PRQuantum-Si Expands Proteus™ Roadshow with Additional U.S. and European CitiesBRANFORD, Conn., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule protein sequencing, today announced the expansion of a roadshow designed to accelerate market education on its Proteus platform and applications for protein sequencing. Since the Company’s June roadshow update, the Proteus roadshow has continued to expand with additional planned stops across the United States and Europe. Upcoming events include Leiden on September 11th, Paris on September 14th, and London on September 15th, followed by the University of Colorado Anschutz Medical
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Quantum-Si IncorporatedSCHEDULE 13D/A - Quantum-Si Inc (0001816431) (Subject)
- PRQuantum-Si to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceBRANFORD, Conn., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule protein sequencing, today announced that it will be participating in the H.C. Wainwright 28th Annual Global Investment Conference taking place at the Lotte New York Palace Hotel, September 14-16, 2026. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will be taking one-on-one meetings throughout the day on Tuesday, September 15, 2026, and Jeff Hawkins will participate in a fireside chat on the same day at 1:30 PM Eastern Time. A live a
- SECSEC Form 10-Q filed by Quantum-Si Incorporated10-Q - Quantum-Si Inc (0001816431) (Filer)
- SECQuantum-Si Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Quantum-Si Inc (0001816431) (Filer)
- PRQuantum-Si Reports Second Quarter 2026 Financial Results and Provides Proteus™ Development UpdateCompany updates anticipated commercial launch of Proteus to Q2 2027, cost-reduction actions expected to extend cash runway into Q4 2028 and highlights estimated new market opportunities for protein sequencing BRANFORD, Conn., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule protein sequencing, today announced financial results for the second quarter ended June 30, 2026. Press Release Highlights Reported second quarter 2026 revenue of $344 thousand during the Proteus transition period.Updated anticipated Proteus launch timeline to Q2 2027 to in
- PRQuantum-Si to Report Second Quarter 2026 Financial Results on August 13, 2026BRANFORD, Conn., July 27, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will report financial results for the second quarter 2026 on Thursday, August 13, 2026. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM EDT. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website u
- SECQuantum-Si Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Quantum-Si Inc (0001816431) (Filer)
QSI FAQ
11 questionsWhat does Quantum-Si Incorporated do?
Quantum-Si incorporated operates first next-generation protein sequencing and genomics platform for healthcare industries. It offers a single molecule detection solution to decode the molecules of life, including sample preparation, single molecule, massively parallel, and protein identification. The company's technology has the applications in proteomics, single cell, transcriptomics, genomics, metabolomics, and drug testing and screening fields. The company is based in Guilford, Connecticut. Quantum-Si incorporated is a subsidiary of 4Catalyzer Corporation.What is the latest news on QSI?
In the last 30 days Quantisnow tracked 7 wire items for QSI: 3 SEC filings, 2 press releases and news items and 2 earnings updates. The most recent was published on November 14, 2026.What is QSI revenue?
Quantum-Si Incorporated (QSI) reported $1.26M of revenue for the twelve months ended Sep 30, 2026. That is down 60.2% from the year before. Revenue for fiscal 2025 was $2.44M.Is QSI profitable?
No. Quantum-Si Incorporated reported a net loss of $85.13M for the twelve months ended Sep 30, 2026.How much cash and debt does QSI have?
Quantum-Si Incorporated reported $25.58M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does QSI stock trade?
Quantum-Si Incorporated (QSI) is listed on NASDAQ.What sector and industry is QSI in?
Quantum-Si Incorporated operates in the Industrials sector, Industrial Machinery/Components industry.When did Quantum-Si Incorporated go public?
Quantum-Si Incorporated (QSI) completed its IPO in 2020.What are analysts saying about QSI?
Across the last 4 analyst actions on Quantum-Si Incorporated, there were 0 upgrades and 1 downgrade. The most recent action was from Alliance Global Partners: Buy with a $3.75 price target on 2025-02-07.What companies are similar to QSI?
Notable peers in the same industry include PACB (Pacific Biosciences of California Inc.), TXG (10x Genomics Inc.), ILMN (Illumina Inc.), TMO (Thermo Fisher Scientific Inc), BRKR (Bruker Corporation). Compare QSI side-by-side with any of them on Quantisnow.How can I track QSI on Quantisnow?
Quantisnow aggregates Quantum-Si Incorporated's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow QSI to receive live email and push alerts on every new disclosure.